CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion

TÜBINGEN, Germany, March 18, 2016 – CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the appointment of three seasoned industry experts to its supervisory board. The new advisors are:

  • Ralf Clemens, M.D., Ph.D., a senior executive in the vaccine industry who has held various senior scientific and business positions, including at GSK Biologicals and Novartis. He chairs CureVac’s scientific advisory board.
  • Baron Jean Stéphenne, M.Sc., M.B.A., who steered GSK Biologicals through very innovative developments and a series of acquisitions to create one of the leading global vaccine companies. He acts as representative of the Bill & Melinda Gates Foundation.
  • Chris Tanner, Ph.D., a finance professional who was responsible for a number of initial public offerings during his tenure as head of corporate finance and capital markets at UBS in Zurich. Since 2006, he has been Chief Financial Officer of Cosmo Pharmaceuticals S.A., for which he led the IPO process.

These advisors join existing supervisory board members Friedrich von Bohlen, Ph.D. (Chairman), Prof. Wolfgang Hartwig, Ph.D., and Mathias Hothum, Ph.D.
Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated, “We are pleased to welcome these highly-respected experts to CureVac’s supervisory board as we continue to advance our mRNA-based medicines to address significant therapeutic needs and global market opportunities.”
Friedrich von Bohlen, Ph.D., Chairman of CureVac’s supervisory board, said, “We are very much looking forward to establishing a close working relationship with our new members. Benefitting from their extensive pharmaceutical industry experience, we feel well-positioned to continue our successful course in the development of mRNA-based medicines for numerous disease areas and indications.”

CureVac’s full supervisory board can be found here.

Download press release as a PDF file

Your contact

Verena Lauterbach
Senior Manager Communications
T: +49 7071 9883 1756
contact via e-mail